Physician

Bhavnish Bucktowarsing, M.D.

According to 2025 Medicare claims, Bhavnish Bucktowarsing, M.D. (NPI: 1235544198) practices nephrology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is KIDNEY & HYPERTENSION CONSULTANTS, INC. (NPI: 1770524696; TIN: 34-1421578) and primary practice location at 44708-6220. Bucktowarsing is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Bucktowarsing's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 364 traditional Medicare patients, billed 3,641 HCPCS/CPT codes, and received $189,087 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,544 prescription claims across 327 beneficiaries totaling $341,895 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 35 claims. Open Payments data shows 53 records totaling $3,602. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $92,299 and ending at $189,087. Concurrently, Part D prescription costs have risen steadily, from $25,773 to $341,895. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	280	2,658	$92,299
2020	431	4,018	$193,138
2021	398	2,784	$153,247
2022	387	2,970	$166,699
2023	374	6,646	$242,760
2024	364	3,641	$189,087

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	43	375	$25,773
2016	65	805	$34,705
2017	44	649	$34,886
2018	20	57	$2,465
2019	104	344	$41,332
2020	251	1,593	$130,207
2021	314	2,413	$234,344
2022	364	3,119	$876,479
2023	341	2,926	$367,366
2024	327	2,544	$341,895

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	33	$1,595
2022	N/R	N/R	N/R
2023	N/R	32	$364
2024	N/R	35	$378

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	114	133	$120
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	105	276	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	162	257	$62
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	56	78	$59
99454	Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days	38	354	$32

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	239	10,593	$196,751
Lokelma	Sodium Zirconium Cyclosilicate	33	1,580	$29,648
Kerendia	Finerenone	34	1,380	$29,533
Veltassa	Patiromer Calcium Sorbitex	26	986	$29,013
Velphoro	Sucroferric Oxyhydroxide	11	330	$17,783

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$251
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	16	$127

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	53	$3,602	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bhavnish Bucktowarsing, M.D.?

Tedicare shows public-source Medicare data for Bhavnish Bucktowarsing, M.D. (NPI 1235544198), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bhavnish Bucktowarsing, M.D. have ACO affiliation data?

Bhavnish Bucktowarsing, M.D. is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Bhavnish Bucktowarsing, M.D.?

Bhavnish Bucktowarsing, M.D. is linked to KIDNEY & HYPERTENSION CONSULTANTS, INC. (billing NPI 1770524696) in the available physician profile data.

Does Bhavnish Bucktowarsing, M.D. have Open Payments data?

Bhavnish Bucktowarsing, M.D. has 53 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.